Q32 Bio Inc. — Director's Dealing 2018

Mar 28, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27

Reporting Person: Vida Ventures, LLC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (395845)		Indirect

Footnotes

F1: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by [five] directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.